Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

April 15, 2014
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business

April 14, 2014
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

Human Health

December 2013

04/12/13
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada

July 2013

08/07/13
Health Canada Provides Direction to Bioniche Life Sciences Inc. Regarding New Drug Submission Filing

April 2013

01/04/13
Bioniche Life Sciences Inc. Regains Sponsorship of Urocidin™

March 2013

07/03/13
Bioniche Life Sciences Inc. Reorganizes One of its Business Units

January 2013

03/01/13
Bioniche Life Sciences Inc. Provides an Update on the Return of Urocidin™ Global Rights

December 2012

21/12/12
Endo Pharmaceuticals Returns Urocidin™ Global Rights to Bioniche Life Sciences Inc.

November 2012

05/11/12
Bioniche Life Sciences Inc. Announces Discontinuation of Current Phase III Clinical Trial with Urocidin™

15/11/11
Bioniche Life Sciences Inc. Congratulates Dr. Alvaro Morales on his Appointment as Member of the Order of Canada

May 2011

17/05/11
Urocidin™ Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.

February 2011

18/02/11
Urocidin™ Phase III Clinical Trial Results To Be Presented At EAU and AUA Conferences

17/02/11
First Patient Enrolled In Second Phase III Clinical Trial Of Urocidin™

15/02/11
Vaccinating Cattle to Protect Human Health a Topic for First International One Health Congress

November 2010

17/11/10
Urocidin Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo

August 2010

20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

February 2010

12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

November 2009

25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

August 2009

24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC

July 2009

10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM

May 2009

22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well

March 2009

31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM

February 2009

18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology

November 2008

24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer

August 2008

18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well

May 2008

13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

March 2008

04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy

February 2008

13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™

August 2007

16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial

May 2007

22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours

April 2007

16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis

November 2006

08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial

02/11/06
Bioniche Expands Patent Portfolio with Three New Patents

June 2006

29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells

May 2006

24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer

23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product

04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product

April 2006

03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials

March 2006

27/03/06
Bioniche to Host Bladder Cancer Roundtable

13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology

February 2006

07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer

July 2005

14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market

June 2005

17/06/05
Bioniche Issues Recall of BetacTM

16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

May 2005

26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment

April 2005

18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®

November 2004

22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins

09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer

July 2004

22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology

June 2004

14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee

May 2004

20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting

March 2004

29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study


Newsroom

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy